ArticlePloS one2012

High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain.

Annika Järviluoma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.